OUR TECHNOLOGY
Our drugs are aimed at modulating a patient’s own immune system to enable it to overcome cancer or auto-immune conditions. Since our screening platform is unique, we believe our platform-derived targets are also unique. Hence, they confer a built-in advantage in developing a range of targets for immunotherapy. 4C Biomed has prioritised and experimentally validated, and is currently developing, antibodies in relation to the most promising of these targets.

Isotype Control ANTIBODY

Anti-4CB-1 ANTIBODY

Cancer cells were pre-incubated for one-hour with anti-4CB-1 or isotype control antibody. After one-hour, autologous TILs were co-cultured with the cancer cells, together with CellEvent Caspase 3/7 detection reagent. Plates were placed in Incucyte ZOOM system and scanned every hour. Green events represent Caspase 3/7 positive events, reflecting specific killing of cancer cells.